EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference as follows:

             
Date: Thursday, May 4, 2017
 
Time: 10:00 a.m. EDT
 
Location:

The InterContinental Boston Hotel

 

The presentation will be webcast live at the aforementioned time, and archived for 90 days thereafter, via the company’s website at www.eagleus.com, under the Investors Section and is also available at http://edge.media-server.com/m/p/m7pheguw.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
24/04/2017

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarte...

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at . About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meani...

8h / 6m 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Au...

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m. Eastern Time. The Company is delivering a Notice of Internet Availability of Proxy Materials (“Notice”) to stockholders of record as of the close of business on Au...

September 17, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Director...

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi” Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders and serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. In connection w...

August 28, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. The Company’s bylaws establish certain procedural ...

August 18, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BEND...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before ...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch